Clinical Trial Results: Positive or negative results from clinical trials for Compugen's cancer immunotherapy drug candidates heavily influence investor sentiment and stock price.

Regulatory Approvals: Decisions by regulatory bodies like the FDA regarding drug approvals significantly impact the perceived value of Compugen's pipeline and its stock.

Partnerships & Collaborations: Strategic alliances with pharmaceutical companies can boost investor confidence and provide financial resources, affecting the stock price.

Market Sentiment: Overall market trends, particularly in the biotechnology and pharmaceutical sectors, can influence CGEN.US stock, regardless of company-specific news.

Financial Performance: Compugen's cash position, revenue, and profitability (or lack thereof) are key factors investors consider when evaluating the stock's worth.

Competition: The competitive landscape in the cancer immunotherapy field, including progress by rival companies, can impact investor perception of Compugen's market share and potential.

Intellectual Property: The strength and breadth of Compugen's patent portfolio related to its drug candidates are vital to its long-term prospects and affect its stock price.

Economic Conditions: Broader macroeconomic factors, such as interest rates, inflation, and economic growth, can impact investor risk appetite and influence stock valuations across all sectors.